Drug intelligence / Profile preview

anhydrovinblastine

Development stage: Phase 1
Modality: Small Molecules
Administration: Intravenous

Overview

Anhydrovinblastine is a semisynthetic derivative of the vinca alkaloid vinblastine, originally derived from the periwinkle plant *Catharanthus roseus*. It acts as a cell cycle-specific anti-mitotic agent by binding to tubulin and inhibiting its polymerization into microtubules, thereby disrupting mitotic spindle assembly and causing tumor cell cycle arrest in the M phase. This mechanism underlies its potential antineoplastic (anticancer) activity. Anhydrovinblastine has been investigated in clinical trials for the treatment of adult solid tumors but development was discontinued[1][2][3][4][5][6].

Other names: anhydrovincaleukoblastine3',4'-didehydroisoleurosine3',4'-dehydroisoleurosine

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on anhydrovinblastine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anhydrovinblastine.

Explore the full profile